An Open, Randomised, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride in Haemodialysis Patients With Hyperphosphataemia

Trial Profile

An Open, Randomised, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride in Haemodialysis Patients With Hyperphosphataemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Fermagate (Primary) ; Sevelamer
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Sponsors INEOS Silicas
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top